HUTCHMED (NASDAQ:HCM) Price Target Lowered to $17.00 at Bank of America

by · The Markets Daily

HUTCHMED (NASDAQ:HCM – Get Free Report) had its price objective cut by Bank of America from $20.00 to $17.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price target suggests a potential upside of 51.66% from the company’s current price.

Other analysts have also recently issued reports about the company. Weiss Ratings cut HUTCHMED from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 29th. Morgan Stanley set a $13.60 target price on shares of HUTCHMED in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, HUTCHMED has a consensus rating of “Hold” and a consensus price target of $15.30.

Check Out Our Latest Report on HUTCHMED

HUTCHMED Trading Down 3.8%

Shares of HCM stock traded down $0.44 on Tuesday, reaching $11.21. 9,446 shares of the company were exchanged, compared to its average volume of 41,757. HUTCHMED has a 1 year low of $9.77 and a 1 year high of $19.50. The business has a 50-day moving average price of $11.65 and a 200 day moving average price of $13.55. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Jane Street Group LLC raised its stake in shares of HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after acquiring an additional 124,771 shares during the period. UBS Group AG raised its stake in shares of HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after acquiring an additional 72,614 shares in the last quarter. Amundi raised its position in HUTCHMED by 41.9% in the 3rd quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after purchasing an additional 65,898 shares in the last quarter. M&G PLC raised its holdings in HUTCHMED by 26.7% in the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after acquiring an additional 54,601 shares in the last quarter. Finally, XY Capital Ltd lifted its position in shares of HUTCHMED by 291.1% during the 3rd quarter. XY Capital Ltd now owns 52,757 shares of the company’s stock worth $831,000 after purchasing an additional 39,266 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

(Get Free Report)

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.

Further Reading